anti uvrag  (Proteintech)

Journal: Pharmaceutical Biology

Article Title: Apigenin attenuates the atherosclerotic lesions through enhancing selective autophagy/lipophagy and promoting RCT process

doi: 10.1080/13880209.2025.2509020

Figure Lengend Snippet: Apigenin activated and promoted autophagy in ApoE −/− mice. (A) Western blot analysis of ULK1, UVRAG and beclin-1 were shown in left, and graph on the right represented the quantification analysis of autophagy proteins normalized by β-actin ( n = 3). (B) Western blot analysis of ATG3, ATG5 and LC3 were shown in left, and graph on the right represented the quantification analysis of autophagy proteins normalized by α-tubulin ( n = 3). (C) The mRNA expression levels of UVRAG, LC3B, Beclin-1 and ATG14 were examined by RT-qPCR ( n = 10). # p < 0.05, ## p < 0.01 vs NC group; * p < 0.05 and ** p < 0.01.

Article Snippet: The following primary antibodies were used: β-actin (ab8226, 1:2000, Abcam, RRID: AB_3696461, UniProt ID: P60709 ), α-tubulin (ab7291, 1:5000, Abcam, RRID: AB_3696470, UniProt ID: P68366 ), ATP-binding cassette transporter 5 (ABCG5) (27722-1-AP, 1:1000, Proteintech, RRID: AB_2880952, UniProt ID: Q9H222 ), Beclin-1 (66665-1-Ig, 1:2000, Proteintech, RRID: AB_2882020, UniProt ID: Q14457 ), unc-51-like autophagy-activating kinase 1 (ULK1) (20986-1-AP, 1:1000, Proteintech, RRID: AB_2878783, UniProt ID: O75385 ), UVRAG (19571-1-AP, 1:1000, Proteintech, RRID: AB_10640523, UniProt ID: Q9P2Y5 ), LC3 (18725-1-AP, 1:2000, Proteintech, RRID: AB_2137745, UniProt ID: Q9GZQ8 ), autophagy related protein 3 (ATG3) (11262-2-AP, 1:1000, Proteintech, RRID: AB_2059234, UniProt ID: Q9NT62 ), autophagy related protein 5 (ATG5) (10181-2-AP, 1:2000, Proteintech, RRID: AB_2062045, UniProt ID: Q9H1Y0 ), scavenger receptor class B type I (SR-BI) (ab217318, 1:2000, Abcam, RRID: AB_3696478, UniProt ID: Q8WTV0 ).

Techniques: Western Blot, Expressing, Quantitative RT-PCR

Journal: PLOS Biology

Article Title: Vps34-orchestrated lipid signaling processes regulate the transitional heterogeneity and functional adaptation of effector regulatory T cells

doi: 10.1371/journal.pbio.3003074

Figure Lengend Snippet: ( A ) Experimental schematic for ablation of Vps34 in mature Tregs during early tumorigenesis. Control or Foxp3 Cre-ERT2 Pik3c3 fl/fl mice were subcutaneously (s.c.) inoculated with MC38 colon adenocarcinoma cells (5 × 10 5 ) or B16F10 melanoma cells (2.5 × 10 5 ; see – ) in the right flank. On days 7 to 11 after tumor inoculation, i.p. injections of TAM (2 mg/mouse dissolved in corn oil) were given daily for a total of 5 injections, and tumor size was measured every other day from 7 (MC38) or 11 (B16F10) days after tumor inoculation until endpoint tumor volume (1.5 × 10 3 mm 3 ) or humane endpoint was reached. i.p., intraperitoneal; TAM, tamoxifen. Mouse image created with BioRender. ( B − D ) Control ( n = 9) or Foxp3 Cre-ERT2 Pik3c3 fl/fl ( n = 8) mice were inoculated with MC38 tumors and treated with TAM as described in ( A ). Tumor growth curves (left) and tumor weights (right) at endpoint (day 21) in control or Foxp3 Cre-ERT2 Pik3c3 fl/fl mice ( B ). Quantification of the frequency of control or Vps34-deficient TCRβ + CD4 + GFP + YFP + Tregs derived from the spleen or MC38 tumor of control or Foxp3 Cre-ERT2 Pik3c3 fl/fl mice at day 21 after tumor inoculation ( C ). Quantification of the ratio of total TCRβ + CD8 + T cells to total TCRβ + CD4 + GFP + Tregs derived from the spleen or MC38 tumor of control or Foxp3 Cre-ERT2 Pik3c3 fl/fl mice at day 21 after tumor inoculation ( D ). ( E ) Tumor growth curves (left) and tumor weights (right) at endpoint (day 23) in control or Foxp3 Cre Atg14 fl/fl mice inoculated with MC38 tumors ( n = 5 per group). ( F ) Tumor growth curves (left) and tumor weights of non-ulcerated tumors (right) at endpoint (day 25) in control ( n = 4 for tumor growth; 3 for tumor weight) or Foxp3 Cre Uvrag fl/fl ( n = 6 for tumor growth; 3 for tumor weight) mice inoculated with MC38 tumors. ( G ) Violin plots showing the activity scores of a curated Vps34-activated eTreg signature (upper; i.e., top 200 [ranked by log 2 FC] downregulated genes [log 2 FC ≤ –0.5 and FDR < 0.05] in Vps34-deficient eTregs [transitional + terminal] versus control eTregs [transitional + terminal] from single-cell transcriptome profiling as described in ; see and for details) or curated Atg14-activated eTreg signature (lower; i.e., downregulated genes [log 2 FC ≤ −0.5 and P < 0.05] in Atg14-deficient eTregs versus control eTregs from mixed BM chimera mice; see and for details) in publicly available scRNA-seq datasets of human Tregs from PBMCs, LN, or tumors in public datasets (GSE139324 ; GSE114727 ; GSE239750 as indicated). BM, bone marrow; LN, lymph node; PBMC, peripheral blood mononuclear cells. Data are shown as mean ± s.e.m. ( B – F ). Two-way ANOVA (tumor volume; B , E , F ), Welch’s t test (tumor weight; B , E, F ), two-tailed Student t test ( C , D) , or Wilcoxon rank-sum test ( G ); NS, not significant. Data are representative of 6 ( B – D ) or 2 ( E , F ) independent experiments. The numerical data underlying the graphs shown in this figure are found in ( B – F ). Genes in the Vps34-activated eTreg signature or Atg14-activated eTreg signature are shown in and were applied to publicly available gene sets as described in the figure and figure legend ( G ).

Article Snippet: Quantitative PCR analysis was performed on the QuantStudio 7 Flex System (Applied Biosystems) using the following probes: Uvrag (Mm 01273471) and Actb (Mm 00607939_s1).

Techniques: Control, Derivative Assay, Activity Assay, Two Tailed Test